How to buy Enanta Pharmaceuticals stock (ENTA)

Enanta Pharmaceuticals is a biotechnology business based in the US. Enanta Pharmaceuticals shares (ENTA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.28 – an increase of 4.15% over the previous week. Enanta Pharmaceuticals employs 145 staff and has a trailing 12-month revenue of around $72 million.

Our top picks for where to buy Enanta Pharmaceuticals stock

Buy Enanta Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Enanta Pharmaceuticals stock price (NASDAQ: ENTA)

Use our graph to track the performance of ENTA stocks over time.

Enanta Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-18.

Latest market close	$6.28
52-week range	$5.70 - $17.80
50-day moving average more info button	$10.06
200-day moving average more info button	$12.58
Wall St. target price	$16.88
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-5.48

Is it a good time to buy Enanta Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Enanta Pharmaceuticals price performance over time

Historical closes compared with the close of $5.86 from 2024-12-19

1 week (2024-12-13)	-2.82%
1 month (2024-11-21)	-37.06%
3 months (2024-09-20)	-48.05%
6 months (2024-06-21)	-50.88%

1 year (2023-12-21)	-34.08%
2 years (2022-12-21)	-87.52%
3 years (2021-12-21)	77.39
5 years (2019-12-20)	63.94

Enanta Pharmaceuticals financials

Revenue TTM	$72 million
Gross profit TTM	$86.2 million
Return on assets TTM	-17.18%
Return on equity TTM	-59.64%
Profit margin	-160.27%
Book value	$7.03
Market Capitalization more info button	$124 million

TTM: trailing 12 months

Enanta Pharmaceuticals share dividends

We're not expecting Enanta Pharmaceuticals to pay a dividend over the next 12 months.

Enanta Pharmaceuticals share price volatility

Over the last 12 months, Enanta Pharmaceuticals's shares have ranged in value from as little as $5.7 up to $17.8. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Enanta Pharmaceuticals's is 0.568. This would suggest that Enanta Pharmaceuticals's shares are less volatile than average (for this exchange).

Enanta Pharmaceuticals overview

Enanta Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts. .

Frequently asked questions

null
What percentage of Enanta Pharmaceuticals is owned by insiders or institutions?
Currently 6.09% of Enanta Pharmaceuticals shares are held by insiders and 100.662% by institutions. How many people work for Enanta Pharmaceuticals?
Latest data suggests 145 work at Enanta Pharmaceuticals. When does the fiscal year end for Enanta Pharmaceuticals?
Enanta Pharmaceuticals's fiscal year ends in September. Where is Enanta Pharmaceuticals based?
Enanta Pharmaceuticals's address is: 500 Arsenal Street, Watertown, MA, United States, 02472 What is Enanta Pharmaceuticals's ISIN number?
Enanta Pharmaceuticals's international securities identification number is: US29251M1062 What is Enanta Pharmaceuticals's CUSIP number?
Enanta Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 29251M106